Coming Together for Better Patient Care - Research Report on Air Methods, Express Scripts, Catamaran Corp, Covance and MedAssets

Wed Mar 6, 2013 8:02am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

NEW YORK,  March 6, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Air
Methods Corporation (NASDAQ: AIRM), Express Scripts Holding Company (NASDAQ:
ESRX), Catamaran Corp (USA) (NASDAQ: CTRX), Covance Inc. (NYSE: CVD) and
MedAssets, Inc. (NASDAQ: MDAS), Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Air Methods Corporation Research Report

Air Methods now provides medical communication services via its DirectCall
Transfer to KentuckyOne Health's 18 hospitals and ambulatory care centers in 
Kentucky. Air Method assists with inter-facility patient transports between
Kentucky One Health-affiliated hospitals and ambulatory care centers and
non-Kentucky One Health medical centers by managing all incoming and outgoing
calls between the health system's hospitals, doctors and other hospitals.
According to  Aaron Todd, CEO-Air Methods, the transfer center service won't
just streamline KentuckyOne's patient transfer process but it will also assist
in ensuring that patients remain in their system. The Full Research Report on
Air Methods Corporation - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:


Express Scripts Holding Company Research Report

Express Scripts' SOCRxATES program combines innovative technology with specially
trained community pharmacists. This program plays an important role in helping
patients improve adherence to chronic therapies, as it aims to improve care for
those with chronic medical conditions. The American Journal of Managed Care
reported this program as a success as pharmacists in the program receiving
computer alerts from Express Scripts closed nearly 10% more adherence-related
gaps in care within 30 days compared to pharmacists not working with the
program. It also showed that the same pharmacists were far more successful in
initiating essential therapies. The Full Research Report on Express Scripts
Holding Company - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


Catamaran Corp (USA) Research Report

Catamaran Corporation, a leading provider of pharmacy benefit management
services and technology posts a record setting year with a 100% increase in
revenue on a year-over-year basis. The company's gross profits reached  $733.4
million  during 2012, compared to  $309.5 million  in 2011. "This past year has
been a transformative period for Catamaran, led by the merger with Catalyst
which doubled our size. Throughout this period, we never lost sight of our goals
and operational plan, which was the foundation for the results we achieved in
2012. Our operational excellence, coupled with the successful progression of our
integrations, yielded another record setting year. The dramatic changes embarked
upon by Catamaran in 2012, combined with the financial savings and clinical
results we delivered to our customers, have created a number of new
opportunities for us," said  Mark Thierer, Chairman and CEO of Catamaran. "The
entire company is focused on continuing to deliver superior results, and we are
well positioned to take advantage of our growth and enhanced capabilities in
2013." The Full Research Report on Catamaran Corp (USA) - including full
detailed breakdown, analyst ratings and price targets - is available to download
free of charge at:


Covance Inc. Research Report

An exclusive alliance and services agreement was sealed between Covance and
M2Gen - a  Moffitt Cancer  center subsidiary and leader in personalized cancer
treatments. The agreement will promote faster patient recruitment in
biomarker-driven oncology trails by offering to match biopharmaceutical clients
to potential patients. Covance will become M2Gen's preferred provider for
DNA/RNA sequencing, gene expression analysis, and genotyping analysis services,
which will be conducted at Covance's genomic lab in  Seattle, Washington.
"Working together, Covance and M2Gen expect to help biopharmaceutical companies
accelerate their drug development programs, make better decisions, and improve
their efforts to develop targeted therapies for cancer patients," said  Ken
Somberg, MD, Chief Medical Officer for Covance and Vice President, Clinical
Development Services. "M2Gen's database is unique in the industry, with clinical
data captured and maintained over the cancer patient's lifetime. This alliance
will help us partner with sponsors as the field of personalized medicine
continues to evolve, and as we work toward a common goal of bringing new
life-saving medicines to patients who need them." The Full Research Report on
Covance Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:


MedAssets, Inc. Research Report

Texas'  third largest public system, University Health System, has recently
engaged MedAssets for a multi-year, comprehensive agreement for a sustainable,
organizational transformation to eliminate inefficiencies, reduce costs and
enhance revenue and performance to improve the quality and safety of care
delivery. "Anticipating the negative financial impact of healthcare reform,
University Health System was looking for a single, comprehensive source for a
cost-effective suite of data and technology-enabled services to quickly improve
our health system's clinical, operational and financial capabilities," said 
Christann Vasquez, Executive Vice President and CEO, University Health System.
"With MedAssets, we found a true partner to help us meet the new business model
of care delivery. We are excited by the positive change to date, and we look
forward to continue to build upon the progress we have already accomplished."
The multi-pronged agreement is based upon a holistic operational improvement and
cost reduction strategy that focuses on process and cultural change in five main
areas across the enterprise: clinical resource utilization, labor, purchased
services, supply expense and revenue capture. Specific MedAssets solutions
engaged are: Process Improvement and Clinical Consulting services, Workforce,
Capital and Construction solutions, Strategic Sourcing, Reimbursement Integrity
and Charge Integrity solutions. The Full Research Report on MedAssets, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email: press@

Main: +1-(408)-745-7826

SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.